89bio to Participate in the Cantor Global Healthcare Conference
21. September 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
08. September 2021 16:15 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
12. August 2021 16:05 ET
|
89bio, Inc.
- Initiated Phase 2b ENLIVEN trial in NASH patients -- Completed enrollment in NASH histology cohort with topline data expected by year-end 2021 - SAN FRANCISCO, Aug. 12, 2021 (GLOBE NEWSWIRE) --...
89bio to Participate in Upcoming Investor Conferences
03. August 2021 16:15 ET
|
89bio, Inc.
SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
02. August 2021 08:30 ET
|
89bio, Inc.
SAN FRANCISCO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in Upcoming Investor Conferences
16. Juni 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
10. Juni 2021 08:30 ET
|
89bio, Inc.
SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
12. Mai 2021 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Present at Upcoming Investor Conferences
05. Mai 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
05. April 2021 08:00 ET
|
89bio, Inc.
- Received written guidance from FDA related to trial design and agreement to use liquid formulation -- ENLIVEN trial to initiate as planned in 2Q21 - SAN FRANCISCO, April 05, 2021 (GLOBE...